By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PhaseBio Pharmaceuticals, Inc. 

4020 Aerial Center Parkway
Suite 101
Morrisville  North Carolina  27560  U.S.A.
Phone: 919-535-8861 Fax: 919-535-8867


SEARCH JOBS



Segment
Start Up





Company News
PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases 6/18/2013 9:30:58 AM
PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes 6/4/2013 10:16:42 AM
PhaseBio Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference 5/29/2013 11:08:58 AM
PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer 12/4/2012 10:50:15 AM
PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes 8/21/2012 9:54:55 AM
PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio 6/5/2012 7:34:43 AM
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease 2/22/2012 6:34:11 AM
PhaseBio Pharmaceuticals, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes 11/15/2011 11:16:02 AM
PhaseBio Pharmaceuticals, Inc. Announces the Appointment of Kathryn J. Gregory Vice President of Business Development 4/27/2011 8:31:32 AM
PhaseBio Pharmaceuticals, Inc. Reaches Key Milestones and Receives $15 Million to Complete Series B Financing 12/2/2010 7:36:33 AM
12
//-->